Eli Lilly’s Oral GLP-1 Orforglipron Successful in Third Phase 3 Trial

What You Should Know: – Eli Lilly and Company has announced positive topline results from its Phase 3 ATTAIN-2 trial, which evaluated orforglipron, an investigational oral GLP-1 receptor agonist, in adults with obesity or overweight and type 2 diabetes. – All three doses of the drug met the primary and all key secondary endpoints, showing ... Read More